3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
46
Phase 1
28
Phase 2
24
Phase 1/2
13
Phase 2/3
3
Phase 4
1
Status
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Other hematologic neoplasm
1
Conditions
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
Cisplatin
29
Carboplatin
28
Gemcitabine
27
Paclitaxel
26
pembrolizumab
24
Capecitabine
16
Pemetrexed
15
Bevacizumab
15
Docetaxel
14
Oxaliplatin
13
Fluorouracil
12
Drug Therapy
12
Nivolumab
10
130-nm albumin-bound paclitaxel
9
Trastuzumab
8
anlotinib
7
Injections
7
Rituximab
6
venetoclax
5
atezolizumab
5
Temozolomide
5
Leucovorin
5
Ipilimumab
5
Lenalidomide
4
Irinotecan
4
Interferon alpha-2
4
Folfox protocol
4
Dexamethasone
4
Azacitidine
4
Albumin-Bound Paclitaxel
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 2/3
×
INDUSTRY
×
Bendamustine Hydrochloride
×
Clear all
NCT05139017
2026-06-04
waveLINE-003
Merck Sharp & Dohme LLC
Phase 2/3
Recruiting
290 enrolled
NCT02763319
2025-07-17
B-MIND
Incyte Corporation
Phase 2/3
Completed
453 enrolled
29 charts
NCT02793583
2022-07-21
UNITY-NHL
TG Therapeutics, Inc.
Phase 2/3
Terminated
710 enrolled
1 FDA